The 56-gene ctDNA panel is a key component of DefineMBC™, the company’s comprehensive blood biopsy for metastatic breast cancerSAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (admi...
Related Keywords
Lloyd Sanders , Epic Sciences Inc , Clinical Experience Program , Linkedin , Epic Sciences , Epic Science , Comprehensive Cancer ,
comparemela.com © 2020. All Rights Reserved.